These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 28141764)

  • 1. CRISPR applications in ophthalmologic genome surgery.
    Cabral T; DiCarlo JE; Justus S; Sengillo JD; Xu Y; Tsang SH
    Curr Opin Ophthalmol; 2017 May; 28(3):252-259. PubMed ID: 28141764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
    Yu W; Wu Z
    Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease.
    Hung SSC; McCaughey T; Swann O; Pébay A; Hewitt AW
    Prog Retin Eye Res; 2016 Jul; 53():1-20. PubMed ID: 27181583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective.
    Ilahibaks NF; Hulsbos MJ; Lei Z; Vader P; Sluijter JPG
    Adv Exp Med Biol; 2023; 1396():315-339. PubMed ID: 36454475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas Genome Surgery in Ophthalmology.
    DiCarlo JE; Sengillo JD; Justus S; Cabral T; Tsang SH; Mahajan VB
    Transl Vis Sci Technol; 2017 May; 6(3):13. PubMed ID: 28573077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current researches and prospects of human induced pluripotent stem cells and gene editing technology of CRISPR/Cas9 in inherited ocular diseases].
    Fan F; Wu JH; Luo Y
    Zhonghua Yan Ke Za Zhi; 2021 Sep; 57(9):712-716. PubMed ID: 34865411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of genome-edited pluripotent stem cells and mice by CRISPR/Cas.
    Horii T; Hatada I
    Endocr J; 2016; 63(3):213-9. PubMed ID: 26743444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials and promising preclinical applications of CRISPR/Cas gene editing.
    Çerçi B; Uzay IA; Kara MK; Dinçer P
    Life Sci; 2023 Jan; 312():121204. PubMed ID: 36403643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-targeting strategies as a platform for ocular gene therapy.
    Kumar S; Fry LE; Wang JH; Martin KR; Hewitt AW; Chen FK; Liu GS
    Prog Retin Eye Res; 2023 Jan; 92():101110. PubMed ID: 35840489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
    Li X; Shi W; Geng LZ; Xu JP
    Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.
    Li ZH; Wang J; Xu JP; Wang J; Yang X
    Mil Med Res; 2023 Mar; 10(1):12. PubMed ID: 36895064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.
    Hu X; Zhang B; Li X; Li M; Wang Y; Dan H; Zhou J; Wei Y; Ge K; Li P; Song Z
    Eye (Lond); 2023 Mar; 37(4):607-617. PubMed ID: 35915232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress and applications of gene editing technology CRISPR/Cas in zebrafish].
    Ouyang J; Xue S; Zhou Q; Cui H
    Sheng Wu Gong Cheng Xue Bao; 2020 Jan; 36(1):1-12. PubMed ID: 32072776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR Systems Suitable for Single AAV Vector Delivery.
    Stevanovic M; Piotter E; McClements ME; MacLaren RE
    Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for the CRISPR-Based Therapeutics.
    Li B; Niu Y; Ji W; Dong Y
    Trends Pharmacol Sci; 2020 Jan; 41(1):55-65. PubMed ID: 31862124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.